Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Community-acquired pneumonia,Acute bacterial sinusitis,Acute bacterial exacerbation of chronic bronchitis,Uncomplicated skin and skin structure infections,Complicated skin and skin structure infections,Complicated intra-abdominal infections,Urinary tract infections,Acute pyelonephritis,Chronic bacterial prostatitis,Inhalational anthrax (post-exposure),Plague
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
400 mg intravenously once daily. Infuse over 60 minutes.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life of moxifloxacin is approximately 11-15 hours in patients with normal renal function; allows once-daily dosing.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Hepatic via glucuronide and sulfate conjugation; CYP450 system not significantly involved.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal (approximately 45-60% as unchanged drug and metabolites); biliary/fecal (approximately 20-25% as unchanged drug and metabolites); total urinary and fecal recovery >95%.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Approximately 40-50% bound to serum proteins, primarily albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Volume of distribution is approximately 2.8 L/kg; indicates extensive tissue penetration, including into lungs, sinuses, skin, and soft tissues.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% (complete immediate bioavailability).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
For GFR <30 m L/min, reduce dose to 400 mg intravenously every 48 hours.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Safety and efficacy not established in pediatric patients under 18 years.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No routine dosage adjustment required based on age alone; monitor renal function and adjust as per renal impairment guidelines.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in patients older than 60 years, those taking corticosteroids, and those with kidney, heart, or lung transplants. Fluoroquinolones may exacerbate muscle weakness in persons with myasthenia gravis. Avoid use in patients with known history of myasthenia gravis.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May prolong QT interval; avoid in patients with known QTc prolongation, uncorrected hypokalemia, or receiving class IA or III antiarrhythmics. Use with caution in patients with CNS disorders (e.g., epilepsy). Discontinue if signs of tendon pain, inflammation, or rupture occur. May cause peripheral neuropathy. Use with caution in patients with renal impairment. Avoid in patients with known hypersensitivity to fluoroquinolones.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to moxifloxacin or any fluoroquinolone; history of tendinopathy with fluoroquinolones; patients with myasthenia gravis; pregnancy (category C); nursing mothers; children <18 years; patients with known QTc prolongation or uncorrected electrolyte disturbances.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. However, avoid alcohol as it may increase risk of dizziness and gastrointestinal side effects. Keep well hydrated.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones are limited. First trimester exposure is not associated with major malformations; however, second and third trimester exposure may be linked to fetal bone and cartilage damage. Use during pregnancy should be reserved for infections where no alternatives exist.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Moxifloxacin is excreted into human milk at very low concentrations. The M/P ratio is approximately 0.68. The estimated infant dose is less than 1% of the maternal dose. Caution is advised due to potential for infant joint damage, but no adverse effects reported. Consider interruption of breastfeeding during therapy and for 48 hours after last dose.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy-induced physiological changes (increased volume of distribution, enhanced renal clearance) may lower moxifloxacin plasma concentrations. However, no specific dose adjustments are recommended due to lack of dedicated pharmacokinetic studies in pregnancy. Standard adult dosing (400 mg IV once daily) is used, with caution and consideration of increased clearance potential.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
AVELOX (moxifloxacin) in sodium chloride 0.8% is a fluoroquinolone antibiotic for intravenous use. Avoid rapid infusion; administer over 60 minutes to reduce risk of infusion-related reactions. Monitor for QT prolongation, especially in patients with electrolyte disturbances or on antiarrhythmics. Avoid in patients with known aortic aneurysm or history of tendinopathy. Use caution in elderly and those with renal impairment. Not recommended for patients with myasthenia gravis due to risk of exacerbation.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is given intravenously (IV) and must be infused slowly over at least 60 minutes.,You may experience side effects like nausea, diarrhea, dizziness, or headache. Report severe or persistent symptoms.,Watch for signs of tendon pain or swelling, especially in the shoulder or calf. Stop the medication and seek medical attention if this occurs.,Avoid driving or operating machinery if you experience dizziness or vision changes.,Tell your doctor if you have a history of heart rhythm problems, seizures, or low potassium/magnesium levels.,Use sunscreen and protective clothing to avoid sun sensitivity reactions while on this medication.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is a Electrolyte that works by Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is: 400 mg intravenously once daily. Infuse over 60 minutes.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER is classified as Category A/B. Fluoroquinolones, including moxifloxacin, are associated with an increased risk of arthropathy in juvenile animals. In humans, data from pregnant women exposed to fluoroquinolones . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.